GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Jiudian Pharmaceutical Co Ltd (SZSE:300705) » Definitions » EBIT

Hunan Jiudian Pharmaceutical Co (SZSE:300705) EBIT : ¥586 Mil (TTM As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Hunan Jiudian Pharmaceutical Co EBIT?

Hunan Jiudian Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2025 was ¥146 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥586 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hunan Jiudian Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2025 was 21.67%. Hunan Jiudian Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 32.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hunan Jiudian Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 7.23%.


Hunan Jiudian Pharmaceutical Co EBIT Historical Data

The historical data trend for Hunan Jiudian Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Jiudian Pharmaceutical Co EBIT Chart

Hunan Jiudian Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.09 242.20 308.64 413.22 590.83

Hunan Jiudian Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.85 176.21 194.21 69.55 146.34

Competitive Comparison of Hunan Jiudian Pharmaceutical Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Jiudian Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Jiudian Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Jiudian Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hunan Jiudian Pharmaceutical Co's EV-to-EBIT falls into.


;
;

Hunan Jiudian Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥586 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Jiudian Pharmaceutical Co  (SZSE:300705) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hunan Jiudian Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=590.964 * ( 1 - 12.13% )/( (2349.91 + 2443.678)/ 2 )
=519.2800668/2396.794
=21.67 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3373.131 - 319.203 - ( 704.018 - max(0, 391.864 - 1601.775+704.018))
=2349.91

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3488.955 - 226.219 - ( 819.058 - max(0, 294.96 - 1676.548+819.058))
=2443.678

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Hunan Jiudian Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=585.376/( ( (1354.66 + max(388.545, 0)) + (1379.188 + max(447.995, 0)) )/ 2 )
=585.376/( ( 1743.205 + 1827.183 )/ 2 )
=585.376/1785.194
=32.79 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(350.503 + 367.705 + 53.257) - (319.203 + 0 + 63.717)
=388.545

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(332.261 + 366.529 + 33.975) - (226.219 + 0 + 58.551)
=447.995

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hunan Jiudian Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2025 )
=586.32/8111.591
=7.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Jiudian Pharmaceutical Co EBIT Related Terms

Thank you for viewing the detailed overview of Hunan Jiudian Pharmaceutical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Jiudian Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.1 Health Avenue, Hunan Liuyang Bio Pharmaceutical Park, Hunan, Changsha, CHN, 410329
Hunan Jiudian Pharmaceutical Co Ltd is a China-based pharmaceutical company specializing in research and development, manufacturing of pharmaceutical products, solid and liquid oral preparations and herbal extract products. It manufactures dirithromycin, levodropropizine and levocetirizine hydrochloride in China. The group's products include active pharmaceutical ingredients, herbal extracts, intermediaries, excipients and finished products.
Executives
Xiong Ying Executives
Zhu Zhi Hong Director
Duan Bin Supervisors
Liang Sheng Hua Supervisors
Zheng Xia Hui Directors, executives
Duan Li Xin Director
Zhu Zhi Yun Director
Li Min Secretary Dong
Fan Peng Yun Executives

Hunan Jiudian Pharmaceutical Co Headlines

No Headlines